A



B

mAb/cept product	non-proprietary name	Date of licensing in the EU
Remicade®	infliximab	13-08-1999
Enbrel®	etanercept	03-02-2000
Humira®	adalimumab	08-09-2003
MabThera® (RA indication)	rituximab	06-07-2006
Orencia®	abatacept	21-05-2007
RoActemra®	tocilizimab	16-01-2009
Simponi®	golimumab	01-10-2009
Cimzia®	certolizumab pegol	01-10-2009
Rilonacept Regeneron®	rilonacept	23-10-2009
Ilaris®	canakinumab	23-10-2009
Benlysta®	belimumab	13-07-2011

Biosimilar	non-proprietary name	Date of licensing in the EU
Omnitrope®	somatropin	12-04-2006
Valtropin®	somatropin	24-04-2006
Binocrit®/Abseamed®/ Epoetin alfa hexal®	epoetin alfa	28-08-2007
Silapo® /Retactrit®	epoetin zeta	18-12-2007
Ratiograstim /Biograstim®/ Tevagrastim®	filgrastim	15-09-2008
Zarzio® /Filgrastim Hexal®	filgrastim	06-02-2009
Nivestim®	filgrastim	08-06-2010